Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1970-12-21
|
pubmed:language |
ita
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0037-878X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
283-6
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:5475744-Administration, Oral,
pubmed-meshheading:5475744-Cardiovascular System,
pubmed-meshheading:5475744-Fibrinolysis,
pubmed-meshheading:5475744-Humans,
pubmed-meshheading:5475744-Injections, Intravenous,
pubmed-meshheading:5475744-Sulfonic Acids,
pubmed-meshheading:5475744-Taurine
|
pubmed:year |
1970
|
pubmed:articleTitle |
[Further aspects of the cardiovascular clinical pharmacology of sulfurated taurine amino acid].
|
pubmed:publicationType |
Journal Article
|